Triptorelin acetate extended-release microspheres - Luye Pharma
Alternative Names: LY-01007Latest Information Update: 28 May 2022
Price :
$50 *
At a glance
- Originator Luye Pharma Group
- Class Antineoplastics; Antivirals; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Endometriosis; Prostate cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Endometriosis in China (IM, Controlled release)
- 28 May 2022 No recent reports of development identified for phase-I development in Prostate-cancer in China (IM, Controlled release)
- 05 Dec 2019 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Prostate cancer released by Luye Pharma